Clinical Trial Update: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis [NA]

View source ↗

Summary

A clinical trial assessing the safety and effects of autologous adipose-derived stromal cells in patients with multiple sclerosis has been withdrawn. No further…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Autologous adipose-derived stromal cells (adipose-derived stromal cells)

Snippet

Sponsor: Ageless Regenerative Institute | Conditions: Multiple Sclerosis, Autoimmune Diseases | NA | Status: WITHDRAWN